Comparing two versions of TJ101 given under the skin to healthy adult men in China

A Randomized, Open-label, Single-dose, Crossover Bioequivalence Study of TJ101 Injection Before and After CMC Change Following Subcutaneous Injection in Healthy Adult Male Subjects in China

This study tests whether a single under-the-skin dose of two TJ101 injection formulations work the same in healthy adult men in China.

Quick facts

• Phase: Phase 1
• Study type: Interventional
• Enrollment: 96 (estimated)
• Ages: 18 Years to 45 Years
• Sex: Male
• Sponsor: TJ Biopharma Co., Ltd. (Industry-sponsored)
• Locations: 1 site (Chengdu, Sichuan)
• Trial ID: NCT07300436 on ClinicalTrials.gov

What this trial studies

This single-center, randomized, open-label, single-dose, two-period crossover trial gives eligible healthy male volunteers a 1.2 mg/kg subcutaneous dose of each TJ101 formulation separated by a washout period. Blood samples will be taken over time to measure drug levels and compare pharmacokinetic profiles between the pre-change and post-change formulations. The main goal is to see if the two formulations are bioequivalent after a chemistry, manufacturing, and controls (CMC) change. Safety and tolerability will also be monitored in the healthy participants.

Who should consider this trial

Good fit: Healthy men aged 18–45 years with BMI 19–28 kg/m2 and weight 50–90 kg who can provide informed consent and complete all visits are ideal candidates.

Not a fit: People with active medical conditions, women, those outside the age/BMI/weight ranges, or anyone allergic to the product are unlikely to benefit from participating.

Why it matters

Potential benefit: If the formulations are equivalent, it could support continued supply and consistent dosing of TJ101 for patients who need it.

How similar studies have performed: Manufacturing-change bioequivalence studies for injectable drugs commonly find comparable pharmacokinetics, but there are no public TJ101-specific results available.

Eligibility criteria

Inclusion Criteria:

* Male subjects aged ≥ 18 and ≤ 45 years;
* Body mass index (BMI): 19-28 kg/m2 (inclusive), weight 50-90 kg (inclusive), with BMI calculated as: BMI = weight (kg) / height2 (m2);
* Results of physical examination, vital signs, laboratory tests, 12-lead ECG, chest X-ray (posteroanterior view), and abdominal B-scan ultrasound are normal or clinically insignificant if abnormal;
* Fully understand the purpose and requirements of this study, voluntarily participate in the clinical study and sign the written informed consent form (ICF), and are able to complete the entire study process as required.

Exclusion Criteria:

* (Screening/Admission interview) Known history of allergy to the investigational product, any of its components, or related products; or a history of allergic diseases such as asthma; or allergic diathesis (e.g., known allergy to two or more substances);
* (Screening/Admission interview) A definite history of diseases of the central nervous, cardiovascular, digestive, respiratory, urinary, or hematological systems, or metabolic disorders, or potential underlying diseases that are judged by the investigator to be clinically significant; or other diseases that the investigator considers unsuitable for participation in a clinical study (e.g., history of mental illness);
* (Screening/Admission interview) History of severe infection, severe trauma, or major surgery within 6 months prior to screening;
* (Screening/Admission interview) History of blood donation, blood loss ≥ 400 mL, or blood transfusion (at least one of the above) within 3 months prior to screening; or plan to donate blood within 3 months after the end of the study;
* Positive test for any of the following infectious diseases: human immunodeficiency virus antibody, hepatitis B surface antigen, hepatitis C virus antibody, Treponema pallidum specific antibody, and syphilis specific antibody;
* (Screening/Admission interview + Networked screening) Participation in any clinical trial of a drug, vaccine, or medical device within 3 months before the first dose (except for those who only signed the ICF but did not receive any drug, vaccine, or device intervention), or participated more than 3 months ago but are still in the follow-up period of a clinical trial or within 5 half-lives of the investigational drug (whichever is longer) before screening;
* (Screening/Admission interview) Use of any prescription drugs within 4 weeks before the first dose \[including but not limited to any drugs that alter hepatic enzyme activity (e.g., glucocorticoids, sex hormones, anticonvulsants, cyclosporine, etc.)\], or use of any over-the-counter drugs (including but not limited to Chinese herbal medicines, compound Chinese herbal preparations, health supplements, etc.) or vitamin supplements within 2 weeks before the first dose;
* (Screening/Admission interview) Prior use of growth hormone drugs;
* Positive for anti-TJ101 anti-drug antibody sample at screening;
* (Screening/Admission interview) History of drug abuse;
* (Screening/Admission interview) Smoke an average of ≥5 cigarettes per day within 3 months prior to screening, or are unable to stop using any tobacco products during the entire study period;
* (Screening/Admission interview) Alcoholic within 3 months prior to screening, defined as weekly alcohol use of more than 14 units (1 unit equals 17.5 mL or 14 g of pure alcohol; alcohol content of different types of alcoholic beverages is indicated by volume ratio, 1 unit of alcohol is approximately equal to 35 mL of 50-proof liquor or 350 mL of 5% beer), or are unwilling to stop alcohol use or consumption of any alcohol-containing products during the study period;
* (Admission period) Positive alcohol breath test or positive urine multi-drug panel test;
* (Screening interview) Difficulty with venipuncture and/or intolerance to intravenous paracentesis/indwelling needle, or have a phobia of needles or blood;
* (Screening/Admission interview) Have plans for procreation or sperm donation from the first dose of the investigational product until 3 months after the last dose, and are unwilling to take reliable contraceptive measures;
* (Screening physical examination) Any condition on the abdomen, such as scars or tattoos, that the investigator judges would interfere with the injection or observation of local reactions at the injection site;
* Other conditions that the investigator considers unsuitable for inclusion in this clinical study.

Where this trial is running

Chengdu, Sichuan

• Chengdu Xinhua Hospital — Chengdu, Sichuan, China (Recruiting)

Study contacts

• Study coordinator: Biwei Zeng

Conditions Healthy Adult Males in China